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Abstract
Background: Neisseria meningitidis is a globally important cause of meningitis and septicaemia. Twelve capsular
groups of meningococci are known, and quadrivalent vaccines against four of these (A, C, W and Y) are available as
plain-polysaccharide and protein-polysaccharide conjugate vaccines. Here we apply contemporary methods to
describe B-cell responses to meningococcal polysaccharide and conjugate vaccines.
Methods: Twenty adults were randomly assigned to receive either a meningococcal plain-polysaccharide or
conjugate vaccine; one month later all received the conjugate vaccine. Blood samples were taken pre-vaccination
and 7, 21 and 28 days after vaccination; B-cell responses were assessed by ELISpot, serum bactericidal assay, flow
cytometry and gene expression microarray.
Results: Seven days after an initial dose of either vaccine, a gene expression signature characteristic of plasmablasts
was detectable. The frequency of newly generated plasma cells (CXCR3+HLA-DR+) and the expression of transcripts
derived from IGKC and IGHG2 correlated with immunogenicity. Notably, using an independent dataset, the
expression of glucosamine (N-acetyl)-6-sulfatase was found to reproducibly correlate with the magnitude of
immune response. Transcriptomic and flow cytometric data revealed depletion of switched memory B cells
following plain-polysaccharide vaccine.
Conclusions: These data describe distinct gene signatures associated with the production of high-avidity antibody
and a plain-polysaccharide-specific signature, possibly linked to polysaccharide-induced hyporesponsiveness.
Background
Polysaccharide-encapsulated organisms are the leading
causes of bacterial meningitis and pneumonia in chil-
dren. Neisseria meningitidis is estimated to cause
500,000 serious illnesses worldwide each year [1].
Clinical outcomes of invasive infection vary by setting
and strain, but even in resource rich countries they
are poor, with permanent neurological sequelae com-
mon and up to 10% of those affected dying [1]. While
susceptibility to invasive meningococcal disease is not
completely understood, an inverse relationship is seen
with the prevalence of complement-dependent serum
bactericidal assay (SBA) titres [2], and the levels of bacteri-
cidal antibody correlate with post-immunisation popula-
tion protection [3].
Meningococci comprise 12 capsular groups, six of
which, A, B, C, W, X and Y, are responsible for the
vast majority of meningococcal disease [4]. Immunisa-
tion with meningococcal capsular polysaccharides
(with the exception of capsular group B polysacchar-
ide) induces capsular group-specific SBA activity [5].
However, meningococcal polysaccharide vaccines pro-
vide only short-term protection in adults, have limited
immunogenicity in early childhood and have been
associated with hyporesponsiveness following subse-
quent doses [6, 7]. These shortcomings have been at-
tributed to the T cell-independent nature of responses
to polysaccharides that do not drive the formation of
immunological memory. Chemical conjugation of the
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polysaccharide to a protein carrier directs T-
dependent responses [8]. Quadrivalent meningococcal
vaccines (MenACWY) are licensed in two forms: plain
polysaccharide or polysaccharide conjugated to a car-
rier protein (CRM197 non-toxic mutant of diphtheria
toxin or tetanus toxoid). While both of these vaccines are
immunogenic in adults, the B-cell responses to these vac-
cines have not been described in detail. In particular, the
mechanisms underlying hyporesponsiveness (inferior re-
sponses to subsequent doses), which is evident after
plain-polysaccharide but not protein-conjugated vac-
cines, have yet to be elucidated [9].
We have previously shown pneumococcal polysacchar-
ide and conjugate vaccines produce distinct B-cell re-
sponses in adults, with the former depleting memory and
B1b-cell subsets [6]. Here, we apply contemporary systems
biology tools (gene expression, multi-parameter flow
cytometry and cellular and serological assays) to describe
B-cell responses to the quadrivalent plain-polysaccharide
vaccine (MenACWY-PS) and quadrivalent conjugate vac-
cine (MenACWY-CRM).
Methods
Study participants and vaccines
Healthy adult volunteers (30–70 years of age) were ran-
domly assigned into four groups to be immunised with
intramuscular MenACWY-CRM (group 1; n = 5), intra-
muscular MenACWY-PS (group 2; n = 5), subcutaneous
MenACWY-PS (group 3; n = 5), or one-fifth dose intra-
muscular MenACWY-PS (group 4; n = 5). Allocation to
groups was performed on a 1:1:1:1 basis, generated by
computer randomisation with block size of 4 and con-
cealed in sequentially labelled opaque envelopes. This
study was open labelled with randomisation occurring at
the point that the opaque envelope corresponding to the
designated study number was opened (just prior to first
vaccination). MenACWY-CRM (Menveo®; Novartis Vac-
cines, Bellario-Rosia, Italy) consisted of N. meningitidis
capsular groups A, C, W and Y oligosaccharides (10, 5,
5 and 5 μg, respectively) individually conjugated to
CRM197 carrier protein. MenACWY-PS (ACWYVax®;
GlaxoSmithKline, Rixensart, Belgium) consisted of N.
meningitidis capsular groups A, C, W and Y capsular
polysaccharides (50 μg each serogroup).
All participants then received intramuscular MenACWY-
CRM vaccine 28 days after the initial meningococcal
vaccine. Blood samples were taken at study days 0
(prior to the first vaccine), 7, 28 (prior to the second
vaccine), 35 and 56. One participant withdrew from the
study. The study was open labelled, with both clinical
staff members and participants aware of the vaccine re-
ceived; however, laboratory staff members were blinded
to the group allocations. An Oxfordshire research
ethics committee approved this study (NRES Commit-
tee South Central Oxford C 12/SC/0275).
Transcriptomic analysis
Total RNA was extracted from 2.5 ml peripheral blood
collected into a PAXgene™ RNA stabilisation tube, using
the Blood RNA Kit (PreAnalytiX, Switzerland). These
RNAs were then globin depleted using GLOBINclear™
(Thermo Fisher scientific, Massachusetts). RNA samples
were randomly allocated to an Illumina® Human
HT12v4.0 Expression BeadChip microarray. RNA was
converted into biotin-labelled cRNA and hybridised to a
BeadChip microarray. Hybridised microarrays were
scanned using an Illumina® iScan scanner by the Well-
come Trust Centre for Human Genetics core facility
(Oxford, UK). Sample transcript profile raw data were
extracted from Illumina® GenomeStudio version 1.9.0.
Negative background intensities for each array were sub-
tracted from their respective transcript intensities prior
to normalisation. Transcript intensities were normalised
using robust spline normalisation [10]. Microarray data
were filtered to return transcripts that were significantly
different from their local background (detection p value
of less than 0.05) in at least 60% of all the samples
assessed. Variance-based statistical methods (sample
transcript intensity distribution boxplots, principal com-
ponent analysis and hierarchical clustering) were used to
quality control microarray and check for sample outliers.
A linear model was fitted with normalised expression
of each transcript as the response variable and each
paired sample and vaccination status as predictors. The
empirical Bayes method was then used to generate mod-
erated t-statistics, moderated F-statistics and log-odds of
differential expression using the eBayes function in the
Limma R package [11].
Gene set and blood transcriptional module analysis
Gene-set enrichment analysis (GSEA) was undertaken on
the entire list of filtered transcripts, ranked by their t-statistic
from Limma, using the GseaPreranked tool in the Java-based
desktop application of GSEA v2.0.14 [12]. Analysis was com-
pleted using the 1910 gene sets in the ‘c7:Immunological sig-
nature’ database identified from microarray experiments of
gene expression in immunological studies (http://www.broa-
dinstitute.org/gsea/msigdb/index.jsp). Blood transcriptional
module analysis was undertaken using the tmod R
package on genes ranked by t-statistic; statistical testing
for module expression was evaluated using the tmod-
CERNOtest function, which is a nonparametric test
working on gene ranks [13]. Module activity scores
were determined by taking the mean of the absolute
log2 fold changes in gene expression.
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Gene Expression Omnibus validation cohort
We utilised a publicly available dataset, acquired from the
genomics data repository Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/), as a validation
cohort. This dataset comprised adults vaccinated with ei-
ther MenACWY-PS (n = 13) or MenACWY-CRM (n = 17),
as described by Li et al. [14]. Series and platform data were
downloaded from GEO using the GEOquery R package
[15]. These data were robust multi-array average (RMA)
normalised and analysed as previously detailed.
Isolation of peripheral blood mononuclear cells and
purification of CD19+ B cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from 35 ml heparinised whole blood using lympho-
prep density centrifugation. Purified CD19+ B cells where
then obtained by anti-CD19-magnetic bead separation
(Miltenyi Biotech, UK) as per the manufacturer’s instruc-
tions using AutoMACs® (Miltenyi Biotech, UK).
Antibodies for flow cytometric characterisation of B cells
and plasma cells
Antibodies for flow cytometric characterisation of B cells
and plasma cells were CD19-FITC (clone HIB19,
ebioscience, UK), CD5-FITC (clone L17F12, ebioscience,
UK), CD38-PE (clone HB7, ebioscience, UK), CD43-PE
(clone 84-3C1, ebioscience, UK), HLA-DR-PerCPCy5.5
(clone L243, Biolegend, Cambridge Bioscience, UK), IgM-
PerCPCy5.5 (clone MHM-88, Biolegend, Cambridge Bio-
science, UK), CD27-PECy7 (clone 0323, ebioscience, UK),
CD3-V500 (clone UCHT1, BD Biosciences, UK), CD14-
V500 (clone M5E2, BD Biosciences, UK), CD16-V500
(clone 3G8, BD Biosciences, UK), CXCR3-APC (clone
G02SH7, Biolegend, Cambridge Bioscience, UK), IgD-
APC (clone IgD26, Miltenyi Biotech, UK) and CD20-
APCH7 (clone L27, BD Biosciences, UK). Propidium
iodide (PI; ebioscience, UK) was used as viability stain.
Flow cytometric characterisation of B cells and plasma cells
Purified, CD19+ B cells, re-suspended in phosphate-
buffered saline (PBS)-EDTA + 0.5% bovine serum al-
bumin (BSA), were added at 2 × 105 cells per well of a
V-bottom, 96-well culture plate in a 50-μl volume.
The B cells were then labelled with a combination of
the above antibodies to give: (1) plasma cells, which
were viable (PI−) CD3−CD14−CD16− CD19+CD20lo/-
CD38hiCD27hi with subsets based on expression of
CXCR3 and HLA-DR; (2) memory B cells, which were viable
(PI−) CD3−CD14−CD16− CD19+CD20+CD43− CD5−CD27+
with subsets based on IgM and IgD expression (IgM+ only,
IgM+IgD+, IgD+ only and switched IgM−IgD−).
The antibodies were incubated on ice in the dark for
30 minutes and then washed twice in 200 μl of PBS-
EDTA + 0.5% BSA, at 250 × g for 10 minutes. The B cells
were then fixed for 10 minutes with BD Cell Fix® (BD
Biosciences UK) at room temperature in the dark and
then washed once as above and resuspended in 200 μl
PBS-EDTA-0.5% BSA. The cells were transferred to
microtubes in a total volume of 350 μl PBS-EDTA-0.5%
BSA and stored at 4 °C overnight. The cells were ana-
lysed on a Beckman-Coulter Cyan Flow Cytometer with
9-colour parameters. The data were acquired using Sum-
mitTM software and analysed using Flow Jo® version
10.0.6 software (Tree Star, USA).
Serum bactericidal assay
Human complement serum bactericidal assays (SBAs) for
detection of meningococcal serogroups A and C were per-
formed at Vaccine Evaluation Unit, Public Health England,
Manchester. Serum samples collected at days 0, 28 and 56
were assessed for human SBA activity against serogroup A
(F8238) and serogroup C (C11). In brief, twofold dilutions
of heat-inactivated sera were incubated with suspensions
of the aforementioned N. meningitidis strains and freshly
thawed exogenous human complement. SBA titres were
expressed as the reciprocal end point serum dilutions
yielding ≥50% killing of bacterial colonies after 60 minutes
of incubation compared with growth at time 0. The lower
limit of quantification for the SBA assays was 4; samples
without detectable SBA activity were assigned an arbitrary
value of 2.
B-cell enzyme-linked immunospot assay
PVDF 96 well plates (Millipore) were coated with
100 μl of either 5 μg/ml (capsular group A and C) of
purified meningococcal polysaccharide (National Insti-
tute for Biological Standards and Control (NIBSC)
98/722 and 07/318) conjugated to 5 μg/ml methylated
human albumin (NIBSC), 10 μg/mL diphtheria toxoid
(Statens Serum Institut 2675) or phosphate-buffered
saline (background control). Prior to cells being
seeded onto the plates, all wells were blocked with
complete medium.
Memory B cells were assessed using cultured ELISpot
performed on blood samples collected at days 0, 28 and
56. PBMCs were suspended in R10 at a concentration of
2 × 106 cells/ml. These cells were cultured with an add-
itional 100 μl of RPMI with 10% newborn bovine serum
(NBBS), Staphylococcus aureus Cowan strain (SAC) at
1:2500 dilution of the Pansorbin cell suspension (Calbio-
chem-Novabiochem), 166 ng/ml pokeweed mitogen
(Sigma-Aldrich) and 3.4 μg/ml CpG oligonucleotide (Invi-
voGEN). The cells were incubated for 6 days at 37 °C in
5% carbon dioxide and 95% humidity, after which time
they were washed and processed as described by Lazarus
et al. [9].
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Quantitative real-time PCR
Total RNA, extracted from PAXgene™ tubes, was reverse
transcribed to cDNA using SuperScript III Reverse Tran-
scriptase (Thermo Fisher scientific, Massachusetts). A pri-
mer sequence specific to the spliced XBP1 isoform was
obtained from the literature, sense 5′-GGTCTGCTGAG
TCCGCAGCAGG-3′ and anti-sense 5′-GGGCTTGGTA-
TATATGTGG-3′ [16]. The last two nucleotides of the
spliced isoform sense primer were modified to 5′-GG
TCTGCTGAGTCCGCAGCACT-3′ to create a primer
complementary to the unspliced XBP1 isoform; specific-
ities of these primers were demonstrated by comparison
of the amplicons run on an agarose (1%) gel (Additional
file 1: Figure S12). GAPDH mRNA expression was used as
an internal control, sense 5′- GAAGGTGAAGGTCGGA
GTC-3′ and anti-sense 5′-GAAGATGGTGATGGGA
TTTC-3′. The real-time PCR (RT-PCR) used the Plat-
inum® SYBR® Green SuperMix-UDG detection system
(with ROX) on a StepOnePlus™ instrument (Thermo
Fisher scientific, Massachusetts). The RT-PCR settings
were 95 °C for 5 minutes, followed by 40 cycles of 95 °C
for 30 s, 50 °C for 30 s, 72 °C for 30 s. Samples were
assayed in triplicate and the median ΔCt (cycle threshold
compared with the internal control GAPDH) used in sub-
sequent analyses.
Results
The study design and demographics are shown in Table 1
and Additional file 2: Table S1, respectively.
The rise in bactericidal antibody following an initial dose
of either plain polysaccharide or conjugate MenACWY
vaccine is similar and is not boosted by a subsequent
dose of conjugate vaccine
We evaluated B-cell responses in 20 healthy adults vacci-
nated with either MenACWY-CRM (group 1, intramuscular,
n= 5) or MenACWY-PS (group 2, intramuscular, n= 5;
group 3, subcutaneous, n = 5; group 4, one-fifth dose
intramuscular, n = 5), followed by an additional dose of
MenACWY-CRM 28 days later. We measured anti-
meningococcal capsular group A (MenA) and C (MenC)
specific SBA titers, ex vivo and cultured antibody-secret-
ing cell (ASC) frequencies using enzyme-linked immu-
nospot (ELISpot), following each vaccination.
The first dose of either MenACWY-CRM or
MenACWY-PS elicited a rise in SBA geometric mean ti-
tres (GMTs) against MenA and MenC 28 days post-
vaccination for all groups (Fig. 1a). One participant
failed to produce a detectable rise in SBA titre to MenC.
The second dose did not induce a further rise in SBA ti-
tres as GMTs 28 days after the first and second dose
were comparable. One participant did not have a detect-
able SBA titre against MenC following the second dose
of vaccine; this participant had a titre of 1:4 after the
first dose. No statistically significant differences were
seen in MenA or MenC SBA GMTs between the four vac-
cine groups after the first or second dose of vaccine
(Fig. 1a). No statistically significant rises in MenA- or
MenC-specific cultured ASCs were detected, either when
vaccine groups were analysed individually or combined;
however, a rise in diphtheria-specific ASCs was observed
after the first dose of MenACWY-CRM (Fig. 1b). MenA-
and MenC-specific ex vivo ASCs were detectable 7 days
after each vaccine, with inferior MenC-specific ex vivo
ASCs seen after the second dose of vaccine in those who
previously received MenACWY-PS (Fig. 1c).
Expansion of recently generated plasma cells can be
detected 7 days after a first dose of MenACWY vaccine but
does not distinguish polysaccharide and conjugate vaccines
Figure 2 shows the plasma cell response following im-
munisation across the four study groups. The total
















Group 1 (n = 5) MenACWY-CRM (i/m) MenACWY-CRM (i/m)
Group 2 (n = 5) MenACWY-PS (i/m) MenACWY-CRM (i/m)
Group 3 (n = 5) MenACWY-PS (s/c) MenACWY-CRM (i/m)
Group 4 (n = 5) MenACWY-PS (1/5 i/m) MenACWY-CRM (i/m)
Immunological phenotypes
SBA (MenA and MenC) ✔ ✔ ✔
B mem ELISpots (MenA, MenC, DT) ✔ ✔ ✔
Systems tools
Flow cytometry ✔ ✔ ✔ ✔ ✔ ✔ ✔
Transcriptomics ✔ ✔ ✔
i/m intramuscular, s/c subcutaneous, 1/5 a fifth of the standard dose was administered, SBA serum bactericidal assay, B mem ELISpots B-cell memory enzyme-linked
immunospot, DT diphtheria toxoid
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plasma cell population (CD19+CD20loCD38hiCD27hi)
rose from baseline to 7 days post-immunisation in all
groups, returning to baseline by day 28 (Fig. 2a, c).
CXCR3 and HLA-DR expression was used to define sub-
sets of plasma cells; CXCR3 is a marker of chemotactic
homing to bone marrow or inflamed tissue and HLA-
DR is a marker of recently generated plasma cells [17].
An expansion of the CXCR3+HLA-DR+ subset 7 days
post-immunisation with either MenACWY-CRM or
MenACWY-PS was observed (Fig. 2e). The CXCR3
+HLA-DR+ subset expanded again in MenACWY-PS +
MenACWY-CRM participants (groups 2, 3 and 4) 7 days
(day 35) after administration of MenACWY-CRM but
not in those immunised with two doses of MenACWY-
CRM (group 1). While the overall frequency of plasma
cells appeared lower at day 35 in group 1 (two doses of
Fig. 1 a MenA- and MenC-specific serum bactericidal assay titres at each study time point, with geometric mean titre (dot) and 95% confidence
intervals (bars) across all groups indicated and group allocation denoted by colour. b MenA-, MenC- and diphtheria toxoid-specific cultured
antibody-secreting cell (ASC) ELISpots at each study time point, with geometric mean concentrations (dot) and 95% confidence intervals (bars)
across all groups indicated and group allocation denoted by colour. Group 1 (G1), MenACWY-CRM (day 0) + MenACWY-CRM (day 28); group 2
(G2), intramuscular MenACWY-PS (day 0) + MenACWY-CRM (day 28); group 3 (G3), subcutaneous MenACWY-PS (day 0) + MenACWY-CRM (day 28);
group 4 (G4), one-fifth dose intramuscular MenACWY-PS (day 0) + MenACWY-CRM (day 28). c MenA-, MenC- and diphtheria toxoid-specific ex vivo
antibody-secreting cell (ASC) ELISpots, 7 days after each dose of vaccine (day 7 and day 35). ***p <0.001, **p < 0.01, *p < 0.05 by Welch’s t-test,
comparing protein-conjugated vaccine (G1) with plain-polysaccharide vaccine (G2, G3 and G4) recipients, or paired t-test between time points
(denoted by horizontal lines)
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MenACWY-CRM), the CXCR3−HLA-DR− population
appeared expanded compared with the other groups
(Fig. 2d, e).
A plasma cell gene signature is evident in whole blood
7 days after the initial dose of MenACWY vaccine with
similarities and differences between plain polysaccharide
and conjugate vaccines
The number of differentially expressed (p < 0.001) tran-
scripts 7 days after the initial vaccination varied from 1
to 74, depending on the vaccine group (Additional file 1:
Figure S1). We identified two transcripts (IGLL1 and
LOC642113) that were differentially expressed in more
than one vaccine group, both of which were shared be-
tween groups 1 and 2 (Additional file 1: Figure S2). Con-
versely, significant overlap was seen between gene sets
identified by GSEA, including up-regulation of gene sets
enriched in IgD-negative B cells and induced 7 days after
trivalent inactivated influenza vaccine (Additional file 1:
Figure S2c). Moreover, hierarchical clustering showed
more grouping by vaccination status (i.e. pre- versus
post-vaccination) than vaccine group, which implies the
former explains more of the variance observed in these
data than the latter (Additional file 1: Figure S2). Given
the hierarchical clustering and the significant overlap in
gene regulation, as well as the small number of
Fig. 2 Phenotypic characterisation of peripheral blood plasma cells (PBMCs) following immunisation. Purified, CD19+ B cells were labelled for
identification of plasma cells at baseline (day 0) and 7 days post first (day 7) and second dose (day 35). Representative plots (group 1 participant)
of CD38hiCD27hi plasma cells (a) and CXCR3 HLA-DR subsets (b) are shown for days 0, 7 and 35, with day 28 included to demonstrate a return to
baseline prior to the second dose. The overall frequencies of total CD38hiCD27hi plasma cells per group (c) and CXCR3 HLA-DR subsets (d) at
baseline and 1 week after each vaccine dose are shown per group. Data are expressed as percentage of total B cells, with bars showing median
frequency (interquartile range). ANOVA were performed within each group and the significant differences are denoted (*p = <0.05). Group 1,
MenACWY-CRM/MenACWY-CRM; group 2, MenACWY-PS (intramuscular)/MenACWY-CRM; group 3, MenACWY-PS (subcutaneous)/MenACWY-CRM;
group, MenACWY-PS (one-fifth dose intramuscular)/MenACWY-CRM. e Proportion of plasma cell subsets (percentage of total) at each study time
point for the conjugate group 1 (n = 5) and polysaccharide groups 2, 3 and 4 (combined, n = 14)
O’Connor et al. Genome Medicine  (2017) 9:11 Page 6 of 15
participants per group, we explored differentially tran-
script expression by combining all four vaccine groups
(Fig. 3a). In this combined analysis, five transcripts were
differentially expressed, three of which were annotated
as antibody segments: LOC651751 (Ig kappa chain V-II
region), LOC642113 (IGKV3D-20) and LOC649923
(Additional file 3: Table S2). The two other differentially
expressed transcripts were a cyclin-dependent kinase in-
hibitor (CDKN2D) and a gene of unknown function
(LOC100131905).
In addition to single-transcript-level analysis, gene set
analysis can be evaluated, which increases statistical power
by incorporating data from other relevant biological
experiments. GSEA (http://www.broadinstitute.org/gsea/)
was undertaken on the entire list of transcripts using the
1910 gene sets in the ‘c7: Immunological signature’ collec-
tion. Of note, 7 days post-MenACWY (combined group
analysis), GSEA demonstrated the up-regulation of gene
sets induced 7 days after trivalent inactivated influenza
and yellow fever vaccines (Additional file 4: Table S3).
Furthermore, GSEA at this time point also indicated
the upregulation of gene sets associated with plasma
cells (Additional file 4: Table S3). Analysis of blood
transcriptional modules also showed enrichment of B-
cell, plasmablast and immunoglobulin modules 7 days
after vaccination (Additional file 1: Figure S3).
Next, we explored the difference in the mRNA tran-
scripts induced by the two vaccines by comparing the
fold-change in transcript expression 7 days (over baseline)
following MenACWY-CRM (group 1) to that induced by
MenACWY-PS (groups 2, 3 and 4); these vaccines differ-
entially regulated a single transcript, PRKAG2, an adeno-
sine monophosphate-activated protein kinase (Additional
file 5: Table S4). GSEA revealed a number of immuno-
logical gene sets that were differentially regulated by these
vaccines; in particular, a number of T cell-associated gene
sets were comparatively upregulated in the MenACWY-
CRM vaccinees (Additional file 6: Table S5).
There is a correlation between transcriptomic and
phenotypic plasma cell responses and vaccine
immunogenicity for capsular group C meningococcal
responses
The relationship between the frequency of total and
plasma cell subsets and day 28 MenA- and MenC-
specific SBA titres (all groups combined) are shown in
Table 2. The most statistically significant correlation was
seen between HLA-DRhi CXCR3+ plasma cells, believed
to represent newly generated plasmablasts, and MenC-
specific SBA titres (Table 2) [17]. On the other hand,
there was no evidence of correlation between these
plasma cell populations and MenA-specific SBA titres.
Furthermore, a statistically significant correlation was
seen between day 7 MenC-specific ex vivo ASC frequen-
cies and day 28 MenC-specific SBA titres, but not be-
tween MenA-specific ex vivo ASC frequencies and
MenA-specific SBA titres (Additional file 1: Figure S6).
Fig. 3 Differential transcript expression and associated p values following quadrivalent meningococcal vaccine (all groups combined). a Seven
days after the initial dose of MenACWY. b Seven days after a second dose of MenACWY. Transcripts with a regression p value <0.001 are
highlighted in green
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We next investigated whether the five transcripts that
were differentially expressed following either MenACWY-
PS or MenACWY-CRM correlated with subsequent mea-
sures of vaccine immunogenicity. The fold-change of two
of these transcripts, corresponding to LOC651751 (Ig
kappa chain V-II region) and LOC649923 (Ig gamma-2
chain C region), correlated with MenC-specific SBA titres
28 days post-vaccination (Additional file 1: Figure S7).
Moreover, the fold-rise in LOC649923 and LOC642113
(IGKV3D-20) also correlated with MenC-specific cul-
tured ASC ELISpots (Additional file 1: Figure S5).
No statistically significant correlations were seen for
any of these transcripts and MenA-specific SBA
titres or cultured MenA-specific ASC ELISpot fre-
quencies at 28 days (Additional file 1: Figures S4
and S5). However, mixed model analysis revealed a
relationship between combined capsular group im-
munogenicity (MenA and MenC SBA titres) and ac-
tivity of B-cell, plasmablast and immunoglobulin
gene modules (Fig. 4).
To identify a parsimonious set of transcripts with fold
changes that had a linear relationship with subsequent im-
munological phenotypes (Table 1), without imposing a
threshold for differential expression, a regression shrink-
age method (LASSO) was used [18, 19]. The fold change
in a single transcript, GNS, at day 7 was significantly asso-
ciated with MenC SBA 28 days after MenACWY when
corrected for multiple testing (Additional file 7: Table S6).
Moreover, the genes selected using the LASSO method
were enriched for genes in pathways such as ‘cytokine sig-
nalling’ and ‘immune system’ (Additional file 8: Table S7).
No gene fold changes were significantly associated with
day 28 MenA-specific SBA titres when corrected for mul-
tiple testing.
Disparate gene expression profiles observed 7 days after
the second dose compared with those seen after the
initial dose of MenACWY
A plot of mRNA transcript fold changes and accompany-
ing p values 7 days after the second dose of quadrivalent
meningococcal vaccine is shown in Fig. 3b. Seven days fol-
lowing the second vaccination (MenACWY-CRM), 448
transcripts were differentially expressed; this represents a
notable enrichment of differentially expressed transcript
(DETs) compared with 7 days following the initial dose of
vaccine (Additional file 1: Figure S3a; Additional file 9:
Table S8). Moreover, a number of these DETs were im-
mune-related, including TGFBR2, which has an im-
portant role in immune regulation, binding TGF-β,
subsequently triggering a signalling cascade that sup-
presses T- and B-cell proliferation and effector func-
tion [20, 21, 22]. Contemporaneously, NFKB2, a
central activator of genes involved in inflammation
and immune function, was upregulated [23]. B cell-
specific transcripts such as FCRLA and BANK1 were
downregulated; conversely, FOXP1, a transcription fac-
tor essential for B-cell development and germinal
centre regulation, was upregulated, as was SIVA1,
which binds to the tail of CD27 (present on a subset of
T and B cells), inducing apoptosis [24].
GSEA of mRNA transcript profiles 7 days after the
second dose of vaccine showed the regulation of several
gene sets, including the downregulation of a ‘switch
memory B cells compared with IgM memory B cells’
gene set (Additional file 10: Table S9). These data were
mirrored by flow cytometric data showing a relative de-
cline in switched memory B cells 7 days after the second
dose of vaccine (Fig. 5).
Next, we assessed transcriptional responses follow-
ing the second dose of vaccine in those who previ-
ously received MenACWY-CRM compared with those
who received a prior dose of MenACWY-PS, finding
32 transcripts that were differentially regulated be-
tween these groups (group 1 versus groups 2, 3 and 4;
Additional file 11: Table S10). Moreover, GSEA of
these data showed the enrichment of a number of
gene sets; of particular interest, the downregulation of
the ‘switched memory B cells compared with IgM
memory B cells’ gene set was found to be driven by
those who previously received a dose of MenACWY-
PS (Additional file 12: Table S11). When the data
were subsetted by initial vaccine the ‘switched mem-
ory B cells compared with IgM memory B cells’ gene
set was exclusively downregulated in the MenACWY-
PS cohort, with a greater enrichment score than for
the combined analysis (data not shown).
Table 2 Correlations between frequency of total and plasma cell subsets and day 28 MenA and MenC-specific serum bactericidal
assay titres
Plasma cell subset MenA SBA correlation (r) MenA SBA correlation (p value) MenC SBA correlation (r) MenC SBA correlation (p value)
Total plasma cells 0.147 0.560 0.615 0.007
HLADR + CXCR3+ 0.364 0.137 0.631 0.005
HLADR-CXCR3+ 0.174 0.489 0.576 0.012
HLADR + CXCR3- 0.204 0.417 0.549 0.018
HLADR-CXCR3- −0.015 0.954 0.504 0.033
MenA capsular group A meningococcus, MenC capsular group C meningococcus, r correlation coefficient
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The correlation between the transcriptomic profile
induced at 7 days and vaccine immunogenicity is
reproduced in an independent dataset
We then explored whether the expression of genes identi-
fied in our data set could be validated in an independent
cohort; for this purpose we utilised a publicly available
dataset, acquired from the genomics data repository Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/).
This dataset comprised adults vaccinated with either
MenACWY-PS (n = 13) or MenACWY-CRM (n = 17), as
described by Li et al. [14]. That study also described up-
regulation of transcripts annotated as ‘immunoglobulin’
7 days post-MenACWY [14]. We assessed whether anti-
body segments that associated with MenC-specific SBA in
our dataset also correlated with immunological data avail-
able in the Li et al. study. However, as different microar-
rays were used in the two studies it was not possible to
directly compare transcripts; instead, comparisons were
made at the level of the respective genes (i.e. IGKC and
IGHG2). While we did not replicate correlations between
these genes and MenC SBA titres, a statistically significant
correlation was seen with anti-diphtheria toxoid antibody
concentrations (Additional file 1: Figure S9). Next, we
evaluated the relationship between GNS expression
and MenC responses in the Li et al. dataset, finding a
statistically significant correlation between the expres-
sion of this gene and day 30 MenC IgG concentra-
tions (Fig. 6).
XBP1 upregulated 7 days after either plain polysaccharide
or conjugate MenACWY vaccine
Interestingly in the Li et al. dataset, 440 transcripts were
differentially regulated 7 days after MenACWY-CRM
compared with MenACWY-PS; amongst the most differ-
entially expressed transcripts were genes involved in re-
sponses to unfolded protein pathway, including XBP1
(Additional file 13: Table S12). Moreover, GSEA showed
significant enrichment of gene sets associated with ‘un-
folded protein response’ and ‘activation of chaperone
genes by XBP1s’ 7 days after MenACWY-CRM com-
pared with the equivalent time point following
MenACWY-PS (Additional file 14: Table S13). Con-
versely, the microarray data in our study did not show
differences in expression of XBP1 between MenACWY-
CRM and MenACWY-PS vaccinees; however, scrutiny of
the XBP1 probe sequences on this microarray platform
implied that these would not be able to distinguish
between the unspliced (XBP1u) and spliced (XBP1s) iso-
forms of this gene, the former being constitutively
expressed and the latter being the potent transcription
factor implicated in plasma cell differentiation [25]. To
address this query, we conducted quantitative PCR using
primers specific for the spliced and unspliced isoforms
of XBP1, finding upregulation of XBP1s but not XBP1u
7 days after an initial dose of either MenACWY-CRM or
MenACWY-PS vaccine (Additional file 1: Figure S11).
However, we did not demonstrate a statistically
Fig. 4 Correlation between B-cell and plasmablast module activity (mean of absolute fold changes) 7 days post-initial vaccine and day 28
MenA- and MenC-specific serum bactericidal assay (SBA) titres. Li.156.0, plasma cells and B cells, immunoglobulins; Li.156.1, plasma cells and
immunoglobulins [14]
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significant difference in the induction of XBP1s between
those who received the conjugated or plain polysacchar-
ide vaccine (p = 0.22).
Discussion
In this report we describe novel and reproducible tran-
scriptional correlates of vaccine immunogenicity.
Seven days after a dose of MenACWY vaccine, plasma
cell responses, measured both phenotypically and at
the transcriptomic level, correlated with subsequent
MenC-specific antibody titres. Notably, 7 days after an
additional dose of MenACWY vaccine, given one
month later, highly disparate responses were observed
compared with the initial dose. Intriguingly, consider-
able differences in transcriptional responses after the
second dose of vaccine were seen in those who re-
ceived a prior dose of MenACWY-PS compared with
those who previously received a MenACWY-CRM vac-
cine, with downregulation of a ‘switched memory B
cell’ gene set exclusively observed in those who previ-
ously received the plain polysaccharide vaccine.
The transcriptomic profile 7 days after the initial dose
of MenACWY vaccine was characterised by differential
expression of transcripts annotated as antibody seg-
ments; fold-changes in IGKC and IGHG2 genes corre-
lated with MenC-specific SBA titres and memory B cell
ELISpots 28 days post-vaccination. IGHG2 encodes the
constant region of the heavy chain of IgG2, which is the
predominant IgG subclass directed to polysaccharide an-
tigens (including those in protein-conjugated meningo-
coccal vaccines) in older children and adults [26, 27, 28].
It is possible to infer from the correlation between the
expression of IGHG2 and MenC-SBA titres that this
gene is a marker of a population of MenC-specific
plasma cells, secreting high avidity complement-fixing
IgG2. While IgG2 is not as efficient at fixing comple-
ment as IgG1, it can activate the classic pathway at high
epitope density and when antibody is at equivalence or
in excess [29]. We were also able to describe statistically
significant relationships between the activity of B-cell,
plasmablast and immunoglobulin gene modules assessed
7 days after vaccination and later measures of vaccine
Fig. 5 Flow cytometric analysis of IgM memory (left) and switched memory (right) B cell populations, shown as the percentage of total B cells
(CD20+) at various study time points (i.e. initial vaccine at day 0 followed by an additional dose at day 28). FDR false discovery rate
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immunogenicity (28 days post-vaccination); this is con-
sistent with previous reports that have correlated these
modules with responses to other vaccinations such as
pneumococcal polysaccharide vaccine and trivalent-
inactivated influenza vaccine [14, 30]. Further descrip-
tion of the B-cell receptor transcript repertoire in this
study is described elsewhere [31].
While we observed a correlation between day 7 MenC-
specific ex vivo ASC frequencies and day 28 MenC-
specific SBA titres, we did not see a statistically significant
correlation between MenA-specific ex vivo ASC frequen-
cies and MenA-specific SBA titres. A possible explanation
for this disparity could be lack of statistical power, given
the modest number of participants assessed; alternatively,
it may be due to intrinsic differences between the ex vivo
ELISpot, which measures total MenA-specific ASCs, and
the MenA-specific SBA, which measures a subset of anti-
bodies with functional activity (bactericidal).
To further investigate predictors of vaccine immuno-
genicity, we identified a minimal set of transcripts that
independently predicted post-vaccination SBA titres
using a shrinkage variable selection algorithm (LASSO);
the resultant gene set was enriched for transcripts in-
volved in pathways such as ‘cytokine signalling’ and the
‘immune system’. A statistically significant association
was seen between the fold rise in GNS at day 7 and day
28 MenC-specific SBA titres. Additionally, a correlation
between day 7 GNS expression and day 30 MenC IgG
concentrations was also observed in the Li et al. cohort.
Glucosamine (N-acetyl)-6-sulfatase (GNS) is a lysosomal
enzyme found in all cells and has been shown to be per-
turbed following yellow fever and live-attenuated influ-
enza vaccine [32, 33]. Deficiencies in GNS result in the
lysosomal storage disorder mucopolysaccharidosis type
IIID (MPS IIID), a condition predominantly charac-
terised by severe neurological manifestations; however,
this condition is also associated with recurrent ear and
upper respiratory infections [34]. These data show a re-
lationship between expression of GNS and antibody re-
sponses against polysaccharide-encapsulated bacteria
and, together with the observations in MPS IIID, indi-
cate a potential role for this gene in controlling infection
caused by encapsulated bacteria [34].
Analysis of day 7 data following the second dose of
vaccine appeared highly disparate from those observed
after the initial dose, with a notable enrichment of DETs.
B cell-specific transcripts, such as FCRLA and BANK1,
were downregulated at this time point; conversely,
FOXP1, which has been shown to repress plasma cell
differentiation, was upregulated [35]. Pro-apoptotic
Fig. 6 Correlation between the log2 fold change from day 0 to day 7 in GNS and MenC-specific IgG concentrations 30 days after MenACWY
vaccine. The Pearson product–moment correlation coefficient (cor) and accompanying p value are displayed
O’Connor et al. Genome Medicine  (2017) 9:11 Page 11 of 15
SIVA1 was also upregulated, which binds to the cyto-
plasmic tail of CD27, expressed by a subpopulation of T
and B cells, including plasma cells [24]. At this time
point we also observed the downregulation of TGFBR2,
which is essential for the normal maintenance of con-
ventional B cells [20]. Concurrently, NFKB2 (subunit of
NF-kB), which is induced downstream of several path-
ways, including signalling via the B-cell receptor (BCR),
was upregulated [36]. While NF-kB is often regarded as
a prototypical pro-inflammatory factor, it also has an
important role in limiting inflammatory responses, for
example by promoting activation-induced cell death of
T and B cells [37]. It is possible to postulate these data
may partly reflect immunoregulatory processes induced
by repeated exposure to recently encountered (or per-
sistent) antigens.
GSEA of gene profiles 7 days after the second dose of
vaccine indicated the downregulation of the ‘switched
memory B cells compared with IgM memory B cells’
gene set; however, this observation was exclusively
driven by individuals who previously received the plain
polysaccharide vaccine. Flow cytometric analysis implied
that this observation was due to a decrease in switched
memory B cells rather than an increase in IgM memory
B cells. While previous data have shown the depletion of
antigen-specific switched memory B cells following poly-
saccharide vaccines, remarkably, we witnessed a reduc-
tion in the total frequency of these cells [6, 38]. Murine
studies have shown polysaccharide vaccines deplete
antigen-specific memory B cells by inducing apoptosis,
which has been proposed as the mechanism underlying
hyporesponsiveness following these vaccines [38]. How-
ever, factors involved in isotype switching, such as TACI
and BAFFR, have been shown to be downregulated by B
cells following administration of capsular group C men-
ingococcal polysaccharide vaccine, resulting in less
BAFF- and APRIL-induced IgG secretion [39]. The
aforementioned study proposed this as an additional
mechanism, independent of B-cell receptor specificity,
by which polysaccharide vaccines induce suppression of
B-cell responses [39]. Importantly, the downregulation
of the ‘switched memory B cells compared with IgM
memory B cells’ gene set was solely observed in individ-
uals who previously received MenACWY-PS, which is
consistent with the notion that hyporesponsiveness is
not a feature of conjugate vaccines [40]. Nevertheless,
these data imply that an additional dose of MenACWY-
CRM one month after MenACWY-PS does not mitigate
the depletion of switched memory B cells, and therefore
theoretically hyporesponsiveness.
As the number of participants involved in this study
was modest, some of the deductions made from this
work merit further confirmatory investigation. To
strengthen some of our conclusions we reproduced
some of our finding in a publicly available dataset. Inter-
estingly, in contrast to the Li et al. study, we did not ob-
serve differences in the expression of XBP1 between
MenACWY-CRM and MenACWY-PS vaccinees; rather,
we found the functional transcript (XBP1s) to be upreg-
ulated 7 days after an initial dose of either vaccine. XBP-
1 is a transcription factor that is a key regulator of major
histocompatibility complex class II expression on B cells
and is critical to the function of highly secretory cells
such as plasma cells [25, 41]. XBP1 is critical for normal
plasma cell secretory function, which would logically ex-
plain its upregulation coinciding with the peak plasma
cell frequency in peripheral blood following vaccination
[25, 42]. Interestingly, XBP1 did not appear to be upreg-
ulated 7 days after plain polysaccharide vaccine in the Li
et al. dataset, which corresponded with modest plasma
cell responses to this vaccine. A possible explanation for
the disparities between our XBP1 findings and those de-
scribed by Li et al. may be differing polysaccharide-
specific plasma cell kinetics due to dissimilarities in the
pre-existing immune status of the study participants.
The appearance of plasma cells in peripheral blood has
been shown to differ between primary and secondary
immune responses, peaking at 10 and 7 days, respect-
ively [43]. While Li et al. observed that the vast majority
of plasma cells induced by the protein-conjugate menin-
gococcal vaccine were carrier protein-specific and that
the plain polysaccharide vaccine induced few plasma
cells 7 days post-vaccination, our data indicated compar-
able plasma cell responses between these vaccines [14].
It may be the case that historical differences in meningo-
coccal nasopharyngeal carriage incidence between these
populations underlie these observations. Importantly,
carriage varies by country; for example, the epidemic of
MenC disease observed in the UK in the late 1990s was
not seen in the US [44]. Furthermore, the UK partici-
pants were older (30–70 years of age, median 55 years,
interquartile range 44–59 years) than the US participants
(18–45 years of age), and therefore have an increased
risk of having previously carried as a function of time
[45]. In addition, these disparities may reflect intrinsic
differences between the vaccines administered in these
studies (here, Menveo® (Novartis Vaccines) and/or
ACWYVax® (GlaxoSmithKline); Li et al., Menomune®
(Sanofi Pasteur) or Menactra® (Sanofi Pasteur)).
In this study we observed similar MenA- and MenC-
specific SBA titres following a single dose of both
MenACWY-PS and MenACWY-CRM, which is con-
sistent with previous immunogenicity data in adults
[46, 47]. No further rise in SBA titres was seen follow-
ing the additional dose of vaccine; this is not surpris-
ing as polysaccharide vaccines do not induce
immunology memory, and a minimal interval of
~4 months is required for effective booster responses
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[48]. Interestingly, we demonstrated inferior MenC-
specific ex vivo ASC frequencies following the second
dose of vaccine in those who previously received the
plain polysaccharide vaccine, compared with those who
received the protein-conjugated vaccine; these data are
consistent with polysaccharide vaccine-induced hypore-
sponsiveness. While this was not seen with regards to
MenA-specific ex vivo ASCs, this may reflect lack of
power to demonstrate statistical significance.
Conclusions
We describe distinct gene signatures that appear to be
associated with the production of high-avidity antibody
and control of B-cell responses after repeated doses of
meningococcal vaccines. We demonstrate the downregu-
lation of a gene set associated with switched memory B
cells that was unique to those who received an initial
dose of plain polysaccharide vaccine, which may repre-
sent an early molecular signal of hyporesponsiveness in-
duced by this vaccine.
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